Ludwig Hammel
Research Subjects
Ludwig Hammel has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Anna Fleischer
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
3 shared publications - Billy Sperlich
Integrative and Experimental Exercise Science & Training, Department of Sport Science, Julius-Maximilians-Universität Würzburg, Würzburg, Germany
3 shared publications - Hannah Labinsky
Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
3 shared publications - Karsten Sebastian Luetkens
Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany
3 shared publications - Marc Schmalzing
Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
3 shared publications - Matthias Fröhlich
Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e88949
Assessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. Objective: This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. Methods: This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). Results: The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. Conclusions: Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.
- 26 October 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e88949
Open AccessAssessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. Objective: This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. Methods: This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). Results: The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. Conclusions: Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.
- Open Access
- 4 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Assessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study (Preprint)
BACKGROUND Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. OBJECTIVE This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. METHODS This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). RESULTS The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. CONCLUSIONS Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.
- 4 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAssessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study (Preprint)
BACKGROUND Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. OBJECTIVE This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. METHODS This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). RESULTS The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. CONCLUSIONS Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.
- Open Access
- 9 January 2025
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 9 (1) , 1-10
COping with Rheumatic Stressors (CORS) questionnaire: validated German translation and cross-cultural adaptation for patients with axSpA
Background: Patients with Rheumatic and Musculoskeletal Diseases, including axial spondyloarthritis (axSpA), may suffer from stressors like pain and functional impairments leading to limitations in their self-perceived health status. The COping with Rheumatic Stressors (CORS) questionnaire was developed to analyze how patients cope with these stressors. The CORS is currently not available in German. Objective: First, to translate, cross-culturally adapt and to linguistically validate the original Dutch CORS into German. Second, to test the pre-final German translation through cognitive debriefing in patients with axSpA. Methodology: The original Dutch CORS underwent a multistep cross-cultural adaptation process, as described by Beaton. It was first independently translated into German by bilingual Dutch-German lay and expert translators. Subsequently, it was translated back from the German version into Dutch. Remaining discrepancies were resolved by a scientific committee, resulting in a pre-final German version. This version was then tested through cognitive debriefing by 10 patients with axSpA across a broad spectrum of sociodemographic backgrounds. Results: Forward and backward translations of the CORS revealed minor discrepancies, mainly based on the degree of formal versus informal language usage, minor semantic errors or unusual syntax, which led to minor modifications in the wording. Reviewed by the scientific committee, the pre-final consensus German version was linguistically validated by cognitive debriefing by 10 patients with axSpA. Cognitive debriefing confirmed and ensured closest linguistic validity for German in Germany and highest equivalence to the Dutch original version. Conclusion: The German CORS was shown to have high cross-cultural and face validity for the assessment of coping with rheumatic stressors.
- 9 January 2025
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 9 (1) , 1-10
Open AccessCOping with Rheumatic Stressors (CORS) questionnaire: validated German translation and cross-cultural adaptation for patients with axSpA
Background: Patients with Rheumatic and Musculoskeletal Diseases, including axial spondyloarthritis (axSpA), may suffer from stressors like pain and functional impairments leading to limitations in their self-perceived health status. The COping with Rheumatic Stressors (CORS) questionnaire was developed to analyze how patients cope with these stressors. The CORS is currently not available in German. Objective: First, to translate, cross-culturally adapt and to linguistically validate the original Dutch CORS into German. Second, to test the pre-final German translation through cognitive debriefing in patients with axSpA. Methodology: The original Dutch CORS underwent a multistep cross-cultural adaptation process, as described by Beaton. It was first independently translated into German by bilingual Dutch-German lay and expert translators. Subsequently, it was translated back from the German version into Dutch. Remaining discrepancies were resolved by a scientific committee, resulting in a pre-final German version. This version was then tested through cognitive debriefing by 10 patients with axSpA across a broad spectrum of sociodemographic backgrounds. Results: Forward and backward translations of the CORS revealed minor discrepancies, mainly based on the degree of formal versus informal language usage, minor semantic errors or unusual syntax, which led to minor modifications in the wording. Reviewed by the scientific committee, the pre-final consensus German version was linguistically validated by cognitive debriefing by 10 patients with axSpA. Cognitive debriefing confirmed and ensured closest linguistic validity for German in Germany and highest equivalence to the Dutch original version. Conclusion: The German CORS was shown to have high cross-cultural and face validity for the assessment of coping with rheumatic stressors.
- Open Access
- 29 April 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (6) , 1143-1154
The exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients – A cross-sectional survey
Background: Patients with axial spondyloarthritis (axSpA) benefit from regular home-based exercise (HbE). In spite of recommendations, a relevant proportion of German axSpA patients does not adhere to recommended HbE practices. To enhance HbE care, we developed the novel digital therapeutic (DTx) “Axia” compliant with the European medical device regulation (MDR). Axia offers a modern app-based HbE solution with patient educative content and further integrated features. Objective: We aimed to assess Axia’s efficacy, attractiveness, and functionality through a survey among axSpA-patients involved in the first user tests. Methods: A mixed-method online questionnaire with 38 items was administered to 37 axSpA volunteers after using Axia. Numeric rating scales (NRS) and likelihood scales were primarily used. Results: HbE frequency significantly increased from a median of 1 day/week to 6 days/week (p < 0.001) by using Axia. Existing HbE practitioners also increased their frequency (median of 4 days/week before, 6 days/week with Axia, p < 0.05). Axia received a median rating of 5 out of 5 stars. On NRS scales, Axia scored a median of 9 for intuitiveness and design, and a median of 8 for entertainment. 64.9% reported improved range of motion, 43.2% reported reduced pain, and 93.6% enhanced disease-specific knowledge. All users recommended Axia to other patients. Conclusion: Axia increases axSpA patients HbE frequency, possibly due to its good intuitiveness and design, leading to reduction in pain and subjective improvement of range of motion. This warrants further investigation in large randomized controlled interventional trials to establish its efficacy conclusively and patients adherence to HbE.
- 29 April 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (6) , 1143-1154
Open AccessThe exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients – A cross-sectional survey
Background: Patients with axial spondyloarthritis (axSpA) benefit from regular home-based exercise (HbE). In spite of recommendations, a relevant proportion of German axSpA patients does not adhere to recommended HbE practices. To enhance HbE care, we developed the novel digital therapeutic (DTx) “Axia” compliant with the European medical device regulation (MDR). Axia offers a modern app-based HbE solution with patient educative content and further integrated features. Objective: We aimed to assess Axia’s efficacy, attractiveness, and functionality through a survey among axSpA-patients involved in the first user tests. Methods: A mixed-method online questionnaire with 38 items was administered to 37 axSpA volunteers after using Axia. Numeric rating scales (NRS) and likelihood scales were primarily used. Results: HbE frequency significantly increased from a median of 1 day/week to 6 days/week (p < 0.001) by using Axia. Existing HbE practitioners also increased their frequency (median of 4 days/week before, 6 days/week with Axia, p < 0.05). Axia received a median rating of 5 out of 5 stars. On NRS scales, Axia scored a median of 9 for intuitiveness and design, and a median of 8 for entertainment. 64.9% reported improved range of motion, 43.2% reported reduced pain, and 93.6% enhanced disease-specific knowledge. All users recommended Axia to other patients. Conclusion: Axia increases axSpA patients HbE frequency, possibly due to its good intuitiveness and design, leading to reduction in pain and subjective improvement of range of motion. This warrants further investigation in large randomized controlled interventional trials to establish its efficacy conclusively and patients adherence to HbE.
- Open Access
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 758-759
POS0983 WORK PARTICIPATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN GERMANY: RESULTS FROM A MULTICENTER, OBSERVATIONAL SURVEY (ATTENTUS-axSpA)
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but also increased economic and social burden due to a significant amount of indirect costs. Data on the different work participation domains in axSpA pts with access to biologic therapies are limited. Objectives: To characterise the different domains of work participation [presenteeism, absenteeism, sick leave, unemployment, disability pensions] in axSpA pts and their associations with demographic and clinical confounders. Methods: Pts with confirmed clinical diagnosis of axSpA were enrolled in a multicenter, observational ATTENTUS survey conducted across Germany (Nov-2019 to Jul-2020). To ensure high data quality, inclusion criteria was verified by external monitoring, followed by evaluation of the domains of impaired work participation, including absenteeism and presenteeism (WPAI). Demographics, clinical parameters and patient related outcomes (PROs) were collected via tablet. This analysis included working age (18–65 years) pts; and excluded students and retired pts. Pts without absenteeism (value=0) and presenteeism ≤20% were defined as no impairment at work. Results: A total of 787 axSpA pts were enrolled in the survey. Seven students, 68 retired pts and 17 pts not fulfilling the inclusion criteria were excluded from this analysis, leaving 695 pts with complete data sets. Baseline data are outlined in Table 1. 50 pts received disability pensions, 29 pts received unemployment benefits, 590 (84.9%) pts reported paid work [part-time: n=132 (22.4%); full-time: n=458 (65.9%)], with 242 (41.0%) pts having no impairments at work. 379 (64.2%) employed pts took sick leave within the previous 12 months (mo) (6 mo: n=11). Absenteeism and presenteeism occurred in 140 (23.7%) and 496 (84.1%) pts, respectively. Pts without impairments were mostly of young age, male sex, well-educated, with low disease activity, less fatigue and shorter duration of morning stiffness, and preserved global and physical functioning. No apparent differences between pts with and without impairment of work participation were observed in terms of biologic treatment, disease duration and BMI. Descriptive characteristics of the study population Conclusion: There was a substantial impact on work participation for axSpA pts, despite numerous available therapeutic options. Pts with impaired work participation compared to pts with no impairment, reported increased fatigue, longer duration of morning stiffness, decreased functional capacity, female sex and a lower level of education. References: [1]Ramoda R et al. Arthritis Res Ther. 2016;78 Disclosure of Interests: Uta Kiltz Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: Abbvie, Amgen, Biogen, Fresenius, GSK, Novartis and Pfizer, Kirsten Hoeper Speakers bureau: Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal and Sanofi. Consultant of: Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal and Sanofi. Ludwig Hammel: None declared, Sebastian Lieb Employee of: Employee of Novartis, Andreas Haehle Employee of: Employee of Novartis, Dirk Meyer-Olson Speakers bureau: Abbvie, Amgen, Berlin Chemie, Bristol Myers Squibb, Cellgene, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Novartis, Pfizer, Sandoz Hexal, Sanofi and UCB, Consultant of: Abbvie, Amgen, Berlin Chemie, Bristol Myers Squibb, Cellgene, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Novartis, Pfizer, Sandoz Hexal, Sanofi and UCB.
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 758-759
Open AccessPOS0983 WORK PARTICIPATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN GERMANY: RESULTS FROM A MULTICENTER, OBSERVATIONAL SURVEY (ATTENTUS-axSpA)
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but also increased economic and social burden due to a significant amount of indirect costs. Data on the different work participation domains in axSpA pts with access to biologic therapies are limited. Objectives: To characterise the different domains of work participation [presenteeism, absenteeism, sick leave, unemployment, disability pensions] in axSpA pts and their associations with demographic and clinical confounders. Methods: Pts with confirmed clinical diagnosis of axSpA were enrolled in a multicenter, observational ATTENTUS survey conducted across Germany (Nov-2019 to Jul-2020). To ensure high data quality, inclusion criteria was verified by external monitoring, followed by evaluation of the domains of impaired work participation, including absenteeism and presenteeism (WPAI). Demographics, clinical parameters and patient related outcomes (PROs) were collected via tablet. This analysis included working age (18–65 years) pts; and excluded students and retired pts. Pts without absenteeism (value=0) and presenteeism ≤20% were defined as no impairment at work. Results: A total of 787 axSpA pts were enrolled in the survey. Seven students, 68 retired pts and 17 pts not fulfilling the inclusion criteria were excluded from this analysis, leaving 695 pts with complete data sets. Baseline data are outlined in Table 1. 50 pts received disability pensions, 29 pts received unemployment benefits, 590 (84.9%) pts reported paid work [part-time: n=132 (22.4%); full-time: n=458 (65.9%)], with 242 (41.0%) pts having no impairments at work. 379 (64.2%) employed pts took sick leave within the previous 12 months (mo) (6 mo: n=11). Absenteeism and presenteeism occurred in 140 (23.7%) and 496 (84.1%) pts, respectively. Pts without impairments were mostly of young age, male sex, well-educated, with low disease activity, less fatigue and shorter duration of morning stiffness, and preserved global and physical functioning. No apparent differences between pts with and without impairment of work participation were observed in terms of biologic treatment, disease duration and BMI. Descriptive characteristics of the study population Conclusion: There was a substantial impact on work participation for axSpA pts, despite numerous available therapeutic options. Pts with impaired work participation compared to pts with no impairment, reported increased fatigue, longer duration of morning stiffness, decreased functional capacity, female sex and a lower level of education. References: [1]Ramoda R et al. Arthritis Res Ther. 2016;78 Disclosure of Interests: Uta Kiltz Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: Abbvie, Amgen, Biogen, Fresenius, GSK, Novartis and Pfizer, Kirsten Hoeper Speakers bureau: Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal and Sanofi. Consultant of: Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal and Sanofi. Ludwig Hammel: None declared, Sebastian Lieb Employee of: Employee of Novartis, Andreas Haehle Employee of: Employee of Novartis, Dirk Meyer-Olson Speakers bureau: Abbvie, Amgen, Berlin Chemie, Bristol Myers Squibb, Cellgene, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Novartis, Pfizer, Sandoz Hexal, Sanofi and UCB, Consultant of: Abbvie, Amgen, Berlin Chemie, Bristol Myers Squibb, Cellgene, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Novartis, Pfizer, Sandoz Hexal, Sanofi and UCB.
- 15 March 2019
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 78 (4) , 372-381
Versorgungssituation von Patienten mit ankylosierender Spondylitis und Psoriasisarthritis in Deutschland
- 15 March 2019
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 78 (4) , 372-381
Versorgungssituation von Patienten mit ankylosierender Spondylitis und Psoriasisarthritis in Deutschland
- Open Access
- 25 February 2008
- Published by Georg Thieme Verlag KG in Aktuelle Rheumatologie
- Vol. 33 (1) , 53-59
Aktuelle Trends in Diagnosestellung und Therapie der Spondylitis ankylosans - Ergebnisse einer Patientenbefragung
Hintergrund: In der Mitgliederzeitschrift der Deutschen Vereinigung Morbus Bechterew e. V. vom Dezember 2005 wurde ein 5-seitiger Fragebogen veröffentlicht mit 33 Fragen zur Diagnose, zur Krankheitsaktivität, zur stationären und medikamentösen Therapie sowie zu den Auswirkungen der neuesten Gesundheitsreformgesetze. Der Fragebogen wurde von 908 Patienten beantwortet. Ein Vergleich mit den Ergebnissen 1 œ Jahre früher ermöglicht Rückschlüsse auf gegenwärtige Trends in der Therapie der ankylosierenden Spondylitis (AS). Ergebnisse: Bei einem Drittel der Patienten ist die AS mit einer anderen Grunderkrankung assoziiert: bei 19 % mit einer Psoriasis, bei 13 % mit einer entzündlichen Darmerkrankung und bei 5 % mit einer reaktiven Arthritis. Unter den Begleitmanifestationen war die periphere Oligoarthritis mit 71 % besonders häufig, gefolgt von Enthesitiden bei 41 % und Uveitis bei 30 % der Patienten. Im Jahr 2005 wurden 8 % der Patienten in einem Akutkrankenhaus behandelt. Im Jahr 2004 waren es noch 10 %. In jedem der beiden Jahre suchten 15 % der Patienten eine Rehabilitationseinrichtung auf. Nur 44 % der Patienten hatten jemals an einer krankheitsspezifischen Patientenschulung teilgenommen, und zwar durchschnittlich bei 3,2 Rehabilitationsmaßnahmen mit durchschnittlich 7,9 Schulungsstunden. An einer Rehabilitationsmaßnahme, die auch Radon-Therapie beinhaltete, hatten 28 % der Patienten (32 % der männlichen und 22 % der weiblichen Patienten) mindestens einmal teilgenommen, und zwar durchschnittlich bei 5,9 Rehabilitationsaufenthalten. 74 % dieser Patienten hatten das Radon in einem Stollen inhaliert, 34 % hatten (ausschließlich oder auch) Radon-Wannenbäder genommen. Die Hälfte der Patienten nahm im Jahr 2005 regelmäßig antirheumatische Medikamente, ein weiteres Drittel gelegentlich. Der Anteil, der 2005 ohne antirheumatische Medikamente auskam, betrug 20 %. Bei der Befragung im Juni 2004 gaben nur 12 % der Antwortenden an, in den 12 Monaten davor keine Antirheumatika benötigt zu haben. 60 % der Antwortenden (1 œ Jahre davor 63 %) wurden mit nichtsteroidalen Antirheumatika (NSAR) behandelt, 15 % (27 %) mit Coxiben, 14 % (17 %) mit Kortikosteroiden, 9 % (11 %) mit Sulfasalazin, 6,7 (5,7 %) mit Methotrexat, 8,5 % (5,5 %) mit TNF-α-Inhibitoren, und 0,3 % (0,8 %) hatten sich einer Therapie mit Radium-224-Chlorid unterzogen. Die Abbruchrate betrug bei den TNF-α-Inhibitoren 31 %, bei der Radium-224-Therapie nur 10 %. Eine mindestens 50 %ige Besserung der Schmerzen wurde bei 54 % der mit TNF-α-Inhibitoren behandelten Patienten und bei 47 % der mit Radium-224-Chlorid behandelten Patienten erreicht. Männliche und weibliche Patienten sowie Patienten mit unterschiedlichen Diagnosen unterschieden sich signifikant im Spektrum der in Anspruch genommenen Medikamente. Background: In the membership journal of the Ankylosing Spondylitis Patient Organisation in Germany (Deutsche Vereinigung Morbus Bechterew, DVMB) of December 2005 a questionnaire was published with 33 questions concerning diagnosis, disease activity, therapy as in-patients and drug therapy. The questionnaire was returned by 908 patients. A comparison with responses to another questionnaire 1 œ years earlier allows to draw conclusions about present trends in the therapy of ankylosing spondylitis (AS). Results: In about one third of the patients AS is associated with another disease: In 19 % with psoriasis, in 13 % with inflammatory bowel disease and in 5 % with reactive arthritis. Among the accompanying symptoms peripheral oligoarthritis was most frequent (71 % of the patients), followed by enthesitis (41 %) and uveitis (30 %). In the year 2005 8 % of the patients were treated in a hospital for acute episodes, compared to 10 % in the year 2004. In each of the two years 15 % of the patients were treated in a rehabilitation facility. Among all patients 44 % had participated in a disease-specific patient education, and this in 3.2 rehabilitation courses with altogether 7.9 education hours on average. Radon therapy was received by 28 % of the patients, on average in 5.9 rehabilitation courses. Among these patients 74 % had inhaled the radon in a radon gallery, 34 % had received (only or in addition) radon therapy in the form of radon baths. Antirheumatic drugs were taken regularly by 49 % in the year 2005, in addition by 32 % occasionally, and 20 % did not need any antirheumatics. In June 2004 only 12 % of the respondents indicated to have taken no antirheumatics in the preceding 12 months. 60 % (1œ years earlier 63 %) were treated with non-steroidal anti-inflammatory drugs (NSAIDs), 15 % (27 %) with Coxibs, 14 % (17 %) with corticosteroids, 9 % (11 %) with sulfasalacine, 6.7 % (5.7 %) with methotrexate, 8.5 % (5.5 %) with TNF-α inhibitors, and 0.3 % (0.8 %) had received injections of radium-224 chloride. The percentage of patients who interrupted the anti-TNF-α therapy was 31 %. For the radium-224 therapy the interruption rate was only 10 %. An improvement of pain by at least 50 % was reported by 54 % of patients treated with TNF-α inhibitors and by 47 % of patients treated with radium-224 chloride. There were significant differences in the spectrum of medications taken between male and female patients and also between patients with different diagnoses.
- 25 February 2008
- Published by Georg Thieme Verlag KG in Aktuelle Rheumatologie
- Vol. 33 (1) , 53-59
Open AccessAktuelle Trends in Diagnosestellung und Therapie der Spondylitis ankylosans - Ergebnisse einer Patientenbefragung
Hintergrund: In der Mitgliederzeitschrift der Deutschen Vereinigung Morbus Bechterew e. V. vom Dezember 2005 wurde ein 5-seitiger Fragebogen veröffentlicht mit 33 Fragen zur Diagnose, zur Krankheitsaktivität, zur stationären und medikamentösen Therapie sowie zu den Auswirkungen der neuesten Gesundheitsreformgesetze. Der Fragebogen wurde von 908 Patienten beantwortet. Ein Vergleich mit den Ergebnissen 1 œ Jahre früher ermöglicht Rückschlüsse auf gegenwärtige Trends in der Therapie der ankylosierenden Spondylitis (AS). Ergebnisse: Bei einem Drittel der Patienten ist die AS mit einer anderen Grunderkrankung assoziiert: bei 19 % mit einer Psoriasis, bei 13 % mit einer entzündlichen Darmerkrankung und bei 5 % mit einer reaktiven Arthritis. Unter den Begleitmanifestationen war die periphere Oligoarthritis mit 71 % besonders häufig, gefolgt von Enthesitiden bei 41 % und Uveitis bei 30 % der Patienten. Im Jahr 2005 wurden 8 % der Patienten in einem Akutkrankenhaus behandelt. Im Jahr 2004 waren es noch 10 %. In jedem der beiden Jahre suchten 15 % der Patienten eine Rehabilitationseinrichtung auf. Nur 44 % der Patienten hatten jemals an einer krankheitsspezifischen Patientenschulung teilgenommen, und zwar durchschnittlich bei 3,2 Rehabilitationsmaßnahmen mit durchschnittlich 7,9 Schulungsstunden. An einer Rehabilitationsmaßnahme, die auch Radon-Therapie beinhaltete, hatten 28 % der Patienten (32 % der männlichen und 22 % der weiblichen Patienten) mindestens einmal teilgenommen, und zwar durchschnittlich bei 5,9 Rehabilitationsaufenthalten. 74 % dieser Patienten hatten das Radon in einem Stollen inhaliert, 34 % hatten (ausschließlich oder auch) Radon-Wannenbäder genommen. Die Hälfte der Patienten nahm im Jahr 2005 regelmäßig antirheumatische Medikamente, ein weiteres Drittel gelegentlich. Der Anteil, der 2005 ohne antirheumatische Medikamente auskam, betrug 20 %. Bei der Befragung im Juni 2004 gaben nur 12 % der Antwortenden an, in den 12 Monaten davor keine Antirheumatika benötigt zu haben. 60 % der Antwortenden (1 œ Jahre davor 63 %) wurden mit nichtsteroidalen Antirheumatika (NSAR) behandelt, 15 % (27 %) mit Coxiben, 14 % (17 %) mit Kortikosteroiden, 9 % (11 %) mit Sulfasalazin, 6,7 (5,7 %) mit Methotrexat, 8,5 % (5,5 %) mit TNF-α-Inhibitoren, und 0,3 % (0,8 %) hatten sich einer Therapie mit Radium-224-Chlorid unterzogen. Die Abbruchrate betrug bei den TNF-α-Inhibitoren 31 %, bei der Radium-224-Therapie nur 10 %. Eine mindestens 50 %ige Besserung der Schmerzen wurde bei 54 % der mit TNF-α-Inhibitoren behandelten Patienten und bei 47 % der mit Radium-224-Chlorid behandelten Patienten erreicht. Männliche und weibliche Patienten sowie Patienten mit unterschiedlichen Diagnosen unterschieden sich signifikant im Spektrum der in Anspruch genommenen Medikamente. Background: In the membership journal of the Ankylosing Spondylitis Patient Organisation in Germany (Deutsche Vereinigung Morbus Bechterew, DVMB) of December 2005 a questionnaire was published with 33 questions concerning diagnosis, disease activity, therapy as in-patients and drug therapy. The questionnaire was returned by 908 patients. A comparison with responses to another questionnaire 1 œ years earlier allows to draw conclusions about present trends in the therapy of ankylosing spondylitis (AS). Results: In about one third of the patients AS is associated with another disease: In 19 % with psoriasis, in 13 % with inflammatory bowel disease and in 5 % with reactive arthritis. Among the accompanying symptoms peripheral oligoarthritis was most frequent (71 % of the patients), followed by enthesitis (41 %) and uveitis (30 %). In the year 2005 8 % of the patients were treated in a hospital for acute episodes, compared to 10 % in the year 2004. In each of the two years 15 % of the patients were treated in a rehabilitation facility. Among all patients 44 % had participated in a disease-specific patient education, and this in 3.2 rehabilitation courses with altogether 7.9 education hours on average. Radon therapy was received by 28 % of the patients, on average in 5.9 rehabilitation courses. Among these patients 74 % had inhaled the radon in a radon gallery, 34 % had received (only or in addition) radon therapy in the form of radon baths. Antirheumatic drugs were taken regularly by 49 % in the year 2005, in addition by 32 % occasionally, and 20 % did not need any antirheumatics. In June 2004 only 12 % of the respondents indicated to have taken no antirheumatics in the preceding 12 months. 60 % (1œ years earlier 63 %) were treated with non-steroidal anti-inflammatory drugs (NSAIDs), 15 % (27 %) with Coxibs, 14 % (17 %) with corticosteroids, 9 % (11 %) with sulfasalacine, 6.7 % (5.7 %) with methotrexate, 8.5 % (5.5 %) with TNF-α inhibitors, and 0.3 % (0.8 %) had received injections of radium-224 chloride. The percentage of patients who interrupted the anti-TNF-α therapy was 31 %. For the radium-224 therapy the interruption rate was only 10 %. An improvement of pain by at least 50 % was reported by 54 % of patients treated with TNF-α inhibitors and by 47 % of patients treated with radium-224 chloride. There were significant differences in the spectrum of medications taken between male and female patients and also between patients with different diagnoses.